Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2012 | 1 |
2013 | 1 |
2014 | 1 |
2020 | 1 |
2021 | 1 |
2022 | 1 |
2024 | 0 |
Search Results
4 results
Results by year
Filters applied: . Clear all
The following term was not found in PubMed: ACH-0141625
Page 1
Protease Inhibitors (HCV).
2022 Jan 25. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–.
2022 Jan 25. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–.
PMID: 31644194
Free Books & Documents.
Review.
At least four HCV protease inhibitors have been approved for use in the United States (boceprevir, glecaprevir, grazoprevir, paritaprevir, simeprevir, telaprevir), and others were evaluated in clinical studies (asunaprevir, danoprevir, faldaprevir, sovaprevir, vedroprevir) …
At least four HCV protease inhibitors have been approved for use in the United States (boceprevir, glecaprevir, grazoprevir, paritaprevir, s …
Current race in the development of DAAs (direct-acting antivirals) against HCV.
De Clercq E.
De Clercq E.
Biochem Pharmacol. 2014 Jun 15;89(4):441-52. doi: 10.1016/j.bcp.2014.04.005. Epub 2014 Apr 13.
Biochem Pharmacol. 2014.
PMID: 24735613
The direct-acting antivirals (DAAs) currently in development for treatment of hepatitis C fall into four categories: (i) NS3/4A protease inhibitors: ABT-450/r, faldaprevir, asunaprevir, GS-9256, vedroprevir (GS-9451), danoprevir, MK-5172, vaniprevir, sovaprevir, ACH-2684, …
The direct-acting antivirals (DAAs) currently in development for treatment of hepatitis C fall into four categories: (i) NS3/4A protease inh …
Item in Clipboard
In silico identification of strong binders of the SARS-CoV-2 receptor-binding domain.
Behloul N, Baha S, Guo Y, Yang Z, Shi R, Meng J.
Behloul N, et al.
Eur J Pharmacol. 2021 Jan 5;890:173701. doi: 10.1016/j.ejphar.2020.173701. Epub 2020 Oct 29.
Eur J Pharmacol. 2021.
PMID: 33130279
Free PMC article.
According to our screening and selection criteria, three approved antivirals (elbasvir, grazoprevir, and sovaprevir) and 4 other drugs (hesperidin, pamaqueside, diosmin, and sitogluside) were identified as potent binders of the RBD. ...
According to our screening and selection criteria, three approved antivirals (elbasvir, grazoprevir, and sovaprevir) and 4 other drug …
Item in Clipboard
Meeting report: 26th International Conference on Antiviral Research.
Vere Hodge RA.
Vere Hodge RA.
Antiviral Res. 2013 Oct;100(1):276-85. doi: 10.1016/j.antiviral.2013.08.006. Epub 2013 Aug 21.
Antiviral Res. 2013.
PMID: 23973733
Free PMC article.
Topics in the clinical symposium included the current status of the anti-HCV compounds sovaprevir, ACH-3102, miravirsen and ALS-2200; the evaluation of single-tablet regimens for HIV infection; and the investigation of cytomegalovirus resistance to CMX001. ...
Topics in the clinical symposium included the current status of the anti-HCV compounds sovaprevir, ACH-3102, miravirsen and ALS-2200; …
Item in Clipboard
Cite
Cite